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Abstract
The reaction of the imidazolyl-4(5)-phosphane ligands 2-isopropylimidazol-4(5)yl-diphenylphosphane
(4-MIP(iPr)) and tris(2-isopropylimidazol-4(5)yl)phosphane (4-TIP(iPr)) towards gold(I) has been
explored and compared to those of analogous 1-methylimidazol-2-ylphosphane ligands. The structure of
[(4-MIP(iPr))AuCl] () shows a linear P-Au-Cl coordination, whereas the 4-TIP(iPr) ligand forms a
dinuclear complex [{(4-TIP(iPr))Au}(2)]Cl(2) (). Here, 4-TIP(iPr) bridges two gold(I) atoms in a
head-to-tail P,N fashion. Complex forms in the presence of the hard Lewis acid ZnCl(2) the bimetallic
complex [AuCl(4-TIP(iPr))ZnCl]Cl (), in which 4-TIP(iPr) bridges the two metal centers. In accordance
with the HSAB concept the Au(I) atom is coordinated by the P atom and the zinc(II) by three N atoms in
a N,N,N fashion. The solid-state structures of the complexes have been elucidated by single-crystal
X-ray analysis. The Au(I)-Au(I) contact in is 2.8821(15) A. The biological activities of all
imidazol-2-yl- and imidazol-4(5)-ylphosphane gold(I) complexes towards nine human cancer cell lines
including seven ovarian cancer cell lines of different sensitivity towards cisplatin and two leukemia cell
lines have been explored.
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Fig. SI1 ESI mass spectrum of 4 in methanol. 
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Fig. SI2 ESI mass spectrum of 5 in methanol. 
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Fig. SI3 Packing in the solid-state structure of 6. View along the crystallographic b-axis. The 
displacement ellipsoids are drawn at a 50 % level, H-atoms are omitted for clarity. 
 
Table SI1 Relative potency of compounds 1 - 5 compared to cisplatin. Ratios of IC50 (cisplatin) and 
IC50 (test compound) were calculated for each cell line, respectively. Missing data result from no 
effects up to 10 µM. 
  Cisplatin 1 2 3 4 5 
A2780 1 1.50 0.29 0.12 0.68 0.14 
A2780cis 1 8.32 1.31 - 1.98 0.92 
SKOV-3 1 3.48 - - - - 
HEY 1 4.20 0.69 0.30 0.89 0.33 
OVCAR-3 1 3.41 0.84 - 0.86 - 
OVCAR-8 1 2.85 0.85 0.91 0.75 0.59 
BG-1 1 3.24 0.61 0.38 1.23 0.41 
HL60 1 0.37 0.14 0.09 3.16 0.09 
K562 1 5.08 1.61 1.18 1.49 0.83 
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